Vascular endothelial growth factor in ovarian cancer patients

Czech version

Authors: I. Sedláková ¹; J. Tošner ¹; O. Kopecký ²; V. Vroblová ²; A. Řezáč ¹; P. Škapinec ¹; C. Andrýs ²
Authors‘ workplace: Porodnická a gynekologická klinika LF UK a FN, Hradec Králové, přednosta doc. MUDr. J. Tošner, CSc. ¹; Ústav klinické imunologie a alergologie FN, Hradec Králové, přednosta prof. MUDr. J. Krejsek, CSc. ²
Published in: Ceska Gynekol 2012; 77(5): 415-420

Overview

Objective:
To compare plasma VEGF (vascular endothelial growth factor) levels in ovarian cancer patients, in patients with benign ovarian tumors and healthy women.

Design:
Prospective study.

Setting:
Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové. Department of Immunology and Alergology, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.

Methods:
VEGF was estimated by ELISA (R&D Systems).

Results:
We found that plasma VEGF levels were associated with the International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO I+II, n=8) Med = 425,53 pg/ml (range 142,30–982,40 pg/ml), (FIGO III+IV, n=29) Med = 941,48 pg/ml (range202,10–2857,80 pg/ml) (p=0,03). Patients with primary ovarian cancer (n=37) had a significantly higher plasma VEGF level Med = 829,93 pg/ml (range142,30–2857,80 pg/ml), compared with patients with benign ovarian tumors (n=15) Med = 426,28 pg/ml (range 32,00–922,20 pg/ml) and healthy women (n=21) Med = 283,13 pg/ml (range 80,50–735,20 pg/ml) (p=0,0003). VEGF levels were lower in plasma (n=79) Med = 575,49 pg/ml (range 55,80–2185,00 pg/ml) compared with VEGF levels in ascitic fluid (n=37) Med = 745,74 pg/ml (range 142,30–2185,00 pg/ml) (p=0,04) in ovarian cancer patients.

Conclusion:
Plasma VEGF assay before primary treatment and the changes during the other treatment should contribute to better understanding of angiogenesis in ovarian cancer patients. Plasma VEGF correlates with the stage of primary ovarian cancer.

Key words:
ovarian cancer, VEGF, bevacizumab, personalised treatment.

Sources

1. Brown, LF., Guidi, AJ., Schnitt, SJ., et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res, 1999, 5, p. 1041–1056.

2. Brustman, H., Naudé, S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynec Oncol, 2002, 84, p. 47–52.

3. Cibula, D., Petruželka, L., a kol. Onkogynekologie. Praha: Grada Publishing, 2009, p. 508.

4. Dvorak, HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol, 2002, 20, p. 4368–4380.

5. Ferrara, N., Gerber, HP., LeCouter, J. The biology of VEGF and its receptors. Nat Med, 2003, 9, p. 669–676.

6. Gadducci, A., Ferdeghini, M., Fanucchi, A., et al. Serum preoperative vascular endothelial growth factor in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res, 1999, 19, p. 1401–1405.

7. Garzetti, GG., Ciavattini, A., Goteri, G., et al. Ki67 antigen immunostaining in serous ovarian tumors: index of proliferative activity, with prognostic significance. Gynec Oncol, 1995, 56, p. 169–174.

8. Hartenbach, EM., Olson, TA., Goswitz, JJ., et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Letters, 1997, 121, p. 169–175.

9. Jain, RK. Molecular regulativ of vessel maturation. Nat Med, 2003, 9, p. 685–693.

10. Lewis, NL., Meropol, NJ. Development of new agents for the treatment of advanced colorectal cancer. Clin Colorectal Cancer, 2003, 3, p. 154–164.

11. Miao, HQ., Lee, P., Lin, H., et al. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J, 2000, 14, p. 2532–2539.

12. Miao, HQ., Klagsbrun, M. Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev, 2000, 19, p. 29–37.

13. Muggia, FM., Braly, PS., Brady, MF., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol, 2000, 18, p. 106–115.

14. Ozawa, CR., Banfi, A., Glazer, NL., et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest, 2004, 113, p. 516–527.

15. Paley, PJ., Staskus, KA., Gebhard, K., et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer, 1997, 80, p. 98–106.

16. Reck, M., Pawel, J., Zatloukal, P., et al. and BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAil). Ann Oncol, 2010, 21, p. 1804–1809.

17. Secord, AA., Darcy, KM., Hutson, A., et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer. A Gynecologic Oncology Group study. Gynec Oncol, 2007, 106, p. 221–232.

18. Sowter, HM., Corps, AN., Evans, AL., et al. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest, 1997, 77, p. 607–614.

19. Tewari, SK., Mehta, SK., Burger, AR., et al. Conservation of in vitro drug resistence patterns in epithelial ovarian carcinoma. Gynec Oncol, 2005, 98, p. 360–368.

20. Yancopoulos, GD., Davis, S., Gale, NW., et al. Vascular-specific growth factors and blood vessel formativ. Nature, 2000, 407, p. 242–248.